1. Executive Summary (Confidence: High)

Headquartered in Zurich, Switzerland, and part of the Rejuveron Life Sciences group, Endogena Therapeutics represents a "paradigm shift" in regenerative medicine.^[46] Unlike traditional stem cell therapies that involve injecting foreign cells, Endogena’s approach focuses on the selective regulation of endogenous adult stem and progenitor cells through small molecules.^[46] Its lead candidate, EA-2353, for Retinitis Pigmentosa, has received both FDA Orphan Drug and Fast Track Designations.^[46] Although its Phase I/IIa trial was recently terminated for "corporate decisions" rather than safety concerns, the program demonstrated preliminary evidence of efficacy, including visual acuity gains in treated patients.^[49] With $35.^[5] million in total funding and a robust pipeline targeting dry Age-Related Macular Degeneration (AMD) and lung disease, Endogena is a frontrunner in the "Endogenous Regeneration" field.^[48]